RayBalance
Follow-On / Biosimilar Differentiation
Evaluating whether administration-site enhancement can provide a differentiated performance layer while preserving the drug product.
Subcutaneous delivery performance
Enabling More Predictable Subcutaneous Drug Delivery
RayBalance is developing a non-reformulation platform intended to help pharmaceutical and device partners address absorption variability at the subcutaneous administration site.
The Challenge
Subcutaneous Delivery Still Has a Variability Problem
Subcutaneous delivery offers clear advantages for patients, providers, payors, and pharmaceutical companies. It can reduce infusion burden, support home administration, improve convenience, and extend the commercial value of important therapeutic franchises.
However, SC delivery performance is not determined by the drug product alone. Absorption may be influenced by the local administration environment, injection-site variability, patient physiology, disease-state factors, molecule characteristics, and delivery workflow.
- SC products may show variable absorption across patient populations.
- IV-to-SC conversion programs may face bioavailability or exposure-distribution constraints.
- Follow-on products may struggle to differentiate without changing the drug.
- Reformulation can create CMC, stability, regulatory, manufacturing, and timing burden.
RayBalance Platform
A Non-Reformulation Approach to SC Delivery Performance
RayBalance is developing a drug-adjacent, administration-site platform to support more predictable subcutaneous absorption while preserving a partner’s existing drug product and development strategy.
The platform focuses on administration-site conditions that contribute to absorption variability, with the goal of supporting more predictable delivery performance.
Partner Drug Product Assets
- Molecule
- Formulation
- Excipient system
- Container closure
- Regulatory strategy
→
RayBalance Administration-Site Platform
- Non-reformulation
- Drug-adjacent
- Administration-site focused
- Partner-specific evaluation
→
Partner-Specific Evidence Path
- Feasibility assessment
- PK evaluation where appropriate
- Usability and integration planning
- Regulatory alignment
Partner Opportunities
Built for Pharmaceutical, Biosimilar, and Device Partners
RayBalance is focused on opportunities where subcutaneous absorption performance, variability, administration workflow, lifecycle strategy, or IV-to-SC transition presents a meaningful development or delivery challenge.
Lifecycle Strategy
Evaluating non-reformulation approaches that may support product differentiation, administration performance, and long-term franchise value.
IV-to-SC Transition
Administration-site enhancement may support greater absorption predictability and practical SC transition strategies.
Delivery-System and Device Partners
RayBalance is evaluating collaborations where administration-site enhancement could complement existing or in-development delivery platforms.
Development Approach
Evidence-Driven and Partner-Specific
RayBalance is building its platform through a staged evidence program focused on administration-site biology, absorption-relevant endpoints, safety, usability, and molecule-specific pharmacokinetic evaluation where appropriate.
Detailed technical information, proprietary methods, device configuration, treatment parameters, and molecule-specific development plans are disclosed only under appropriate confidentiality protections.
1
Strategic Fit
Understand the partner’s product, opportunity, and development context.
2
Feasibility Assessment
Evaluate potential alignment with the administration-performance challenge.
3
Evidence Plan
Define the right evidence strategy for the partner opportunity.
4
Molecule-Specific Evaluation
Conduct PK and other evaluation where appropriate.
5
Regulatory and Integration Alignment
Align on regulatory strategy and delivery-system integration.
Contact
Connect with RayBalance
RayBalance is interested in discussions with pharmaceutical companies, biosimilar manufacturers, medical device companies, and strategic partners evaluating subcutaneous delivery performance, lifecycle strategy, or IV-to-SC transition opportunities.
Please do not submit confidential information through this form.
Business Development Inquiries
3830 Valley Centre Drive, STE 705-224
San Diego, CA 92130
Start a Conversation
Fields marked with an asterisk are required.